DMPK Antibody (9-RY26): sc-134319

DMPK Antibody (9-RY26) is a mouse monoclonal IgG2a kappa light chain antibody that detects the DMPK protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-DMPK antibody (9-RY26) is available as a non-conjugated format. Myotonic dystrophy protein kinase (DMPK) plays a crucial role in muscle function as a multi-domain protein kinase that is activated by G protein second messengers and proteolysis. DMPK involvement in myotonic muscular dystrophy (DM) makes this protein significant, as DM is a genetic disorder characterized by muscle weakness and cardiac conduction defects, primarily affecting skeletal and cardiac muscle. DM pathogenesis links to CTG repeat expansion in the 3′-untranslated region of the DMPK gene, leading to accumulation of mutant DMPK transcripts with extended CUG repeats retained in the nucleus. This retention disrupts normal cellular processes and influences the expression of the DM locus-associated homeodomain protein (DMAHP)/SIX5, contributing to clinical manifestations of the disease. DMPK interacts with various substrates, including myogenin, L-type calcium channels, and Phospholemman (PLM), highlighting DMPK′s multifaceted role in muscle physiology and pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DMPK Antibody (9-RY26) References:

1. DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model.  |  Berul, CI., et al. 1999. J Clin Invest. 103: R1-7. PMID: 10021468
2. Phospholemman is a substrate for myotonic dystrophy protein kinase.  |  Mounsey, JP., et al. 2000. J Biol Chem. 275: 23362-7. PMID: 10811636
3. Myotonic dystrophy protein kinase domains mediate localization, oligomerization, novel catalytic activity, and autoinhibition.  |  Bush, EW., et al. 2000. Biochemistry. 39: 8480-90. PMID: 10913253
4. Reduced expression of DMAHP/SIX5 gene in myotonic dystrophy muscle.  |  Inukai, A., et al. 2000. Muscle Nerve. 23: 1421-6. PMID: 10951446
5. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.  |  Mankodi, A., et al. 2000. Science. 289: 1769-73. PMID: 10976074
6. Fundamental aspects of DMPK optimization of targeted protein degraders.  |  Cantrill, C., et al. 2020. Drug Discov Today. 25: 969-982. PMID: 32298797
7. The role of DMPK science in improving pharmaceutical research and development efficiency.  |  Mak, KK., et al. 2022. Drug Discov Today. 27: 705-729. PMID: 34774767
8. High Resolution Analysis of DMPK Hypermethylation and Repeat Interruptions in Myotonic Dystrophy Type 1.  |  Rasmussen, A., et al. 2022. Genes (Basel). 13: PMID: 35741732
9. ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs).  |  Beaumont, K., et al. 2022. Xenobiotica. 52: 770-785. PMID: 36314242
10. Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.  |  Thornton, CA., et al. 2023. Lancet Neurol. 22: 218-228. PMID: 36804094
11. Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells.  |  Porquet, F., et al. 2023. Mol Ther Nucleic Acids. 32: 857-871. PMID: 37273786
12. Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice.  |  Roberts, R., et al. 1997. Proc Natl Acad Sci U S A. 94: 13221-6. PMID: 9371827

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DMPK Antibody (9-RY26) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-DMPK Antibody (9-RY26) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DMPK Antibody (9-RY26) Specifications

Alternate Product Name: DMPK

Product Clone Name: 9-RY26

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 303-421

Epitope Target: DMPK

Epitope Species: human

Product Reactivity/Detection: DMPK

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for DMPK Antibody (9-RY26): N/A